Nitric oxide synthase inhibitors in post‐myocardial infarction cardiogenic shock—an update

Cardiogenic shock (CS) in acute myocardial infarction, after successful coronary angioplasty, still carries a case fatality rate of 50%. These patients succumb to a systemic metabolic storm, superimposed on extensive myocardial necrosis and stunning. Nitric oxide (NO) overproduction contributes to the pathophysiology of this morbid state. Current data regarding the physiologic effects of NO and nitric oxide synthase (NOS) inhibitors on the cardiovascular system are reviewed. Clinical trials assessing the safety and efficacy of NOS inhibitors in CS are summarized.

[1]  T. Rassaf,et al.  Plasma nitroso compounds are decreased in patients with endothelial dysfunction. , 2006, Journal of the American College of Cardiology.

[2]  J. Lundberg.  Nitric oxide metabolites and cardiovascular disease markers, mediators, or both? , 2006, Journal of the American College of Cardiology.

[3]  N. Uriel,et al.  Nitric Oxide Synthase Inhibitors in Refractory Cardiogenic Shock due to Myocardial Infarction after Percutaneous Coronary Intervention , 2005, Heart Drug.

[4]  E. Weitzberg,et al.  NO generation from nitrite and its role in vascular control. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[5]  H. Nakashima,et al.  Evaluation of neurohumoral activation (adrenomedullin, BNP, catecholamines, etc.) in patients with acute myocardial infarction. , 2004, Internal medicine.

[6]  T. LeJemtel,et al.  Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. , 2004, Journal of the American College of Cardiology.

[7]  J. Hare.  Spatial confinement of isoforms of cardiac nitric-oxide synthase: unravelling the complexities of nitric oxide's cardiobiology , 2004, The Lancet.

[8]  S. Houser,et al.  Myocyte Nitric Oxide Synthase 2 Contributes to Blunted β-Adrenergic Response in Failing Human Hearts by Decreasing Ca2+ Transients , 2004, Circulation.

[9]  M. Gottwik,et al.  Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK). , 2004, European heart journal.

[10]  H. White,et al.  Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. , 2003, Journal of the American College of Cardiology.

[11]  Z. Vered,et al.  LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. , 2003, European heart journal.

[12]  J. Hochman,et al.  Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. , 2003, Circulation.

[13]  G. Heusch,et al.  Effect of NO synthase inhibition on myocardial metabolism during moderate ischemia. , 2003, American journal of physiology. Heart and circulatory physiology.

[14]  L. Sleeper,et al.  Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry , 2003 .

[15]  H. White,et al.  Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. , 2003, Journal of the American College of Cardiology.

[16]  Zvi Vered,et al.  The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure , 2003, European journal of heart failure.

[17]  H. White,et al.  Echocardiographic Predictors of Survival and Response to Early Revascularization in Cardiogenic Shock , 2003, Circulation.

[18]  R. Bache,et al.  Nitric Oxide Modulates Myocardial Oxygen Consumption in the Failing Heart , 2002, Circulation.

[19]  R. Bache,et al.  Inhibition of NO production increases myocardial blood flow and oxygen consumption in congestive heart failure. , 2002, American journal of physiology. Heart and circulatory physiology.

[20]  O. Binah,et al.  Role of Myocardial Inducible Nitric Oxide Synthase in Contractile Dysfunction and &bgr;-Adrenergic Hyporesponsiveness in Rats With Experimental Volume-Overload Heart Failure , 2002, Circulation.

[21]  L. Sleeper,et al.  Trends in cardiogenic shock: report from the SHOCK Study. The SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? , 2001, European heart journal.

[22]  Matos Va,et al.  [Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry]. , 2001, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[23]  H. White,et al.  One-year survival following early revascularization for cardiogenic shock. , 2001, JAMA.

[24]  R. Lange,et al.  Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? , 2000, Journal of the American College of Cardiology.

[25]  K. Takeda,et al.  Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. , 2000, Journal of the American College of Cardiology.

[26]  Z. Vered,et al.  L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. , 2000, Circulation.

[27]  G Kaley,et al.  Myocardial glucose uptake is regulated by nitric oxide via endothelial nitric oxide synthase in Langendorff mouse heart. , 2000, Circulation research.

[28]  H. White,et al.  Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. , 1999, The New England journal of medicine.

[29]  A. Ciampi,et al.  Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. , 1998, European heart journal.

[30]  H. Drexler,et al.  Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. , 1998, Journal of the American College of Cardiology.

[31]  L. Hue,et al.  Inhibition of myocardial glucose uptake by cGMP. , 1998, American journal of physiology. Heart and circulatory physiology.

[32]  R. Chioléro,et al.  Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. , 1997, Critical care medicine.

[33]  H. Nakashima,et al.  Predictors of mortality in patients with acute myocardial infarction and cardiogenic shock. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[34]  Kamil Ugurbil,et al.  Nitric oxide regulation of myocardial O2 consumption and HEP metabolism. , 2005, American journal of physiology. Heart and circulatory physiology.

[35]  V. Menon,et al.  Cardiogenic shock: a summary of the randomized SHOCK trial. , 2003, Congestive heart failure.

[36]  Joao A. C. Lima,et al.  Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms , 2002, Nature.

[37]  R. Califf,et al.  Lack of progress in cardiogenic shock: lessons from the GUSTO trials. , 2000, European heart journal.